Learn More
The importance of HER2 status in breast cancer management has focused attention on the ability of clinical assays to correctly assign HER2 amplification status. There is no consensus as to the best(More)
A 57-year-old man with metastatic melanoma was treated with the survivin inhibitor and antisense oligonucleotide LY2181308 as part of a First-in-Human Dose trial. After 18 months of treatment, he(More)
3007 Background: MPM is a tumor that shows high expression of EGFR. We evaluated OSI-774, a novel EGFR tyrosine kinase inhibitor (TKI) in MPM and correlated tumor molecular expression of the EGFR(More)